Looking for a specific product?

Make a search for products & suppliers, articles & news.

Navamedic reached another all time high

Navamedic ASA, the Norwegian pharmaceutical products company, today announced its fourth quarter and 2011 full year results. Sales reached yet another all time high in the fourth quarter and profit margins improved significantly. Navamedic also made its debut in the generic pharmaceuticals market in the quarter.

"The combination of increasing sales and profitability in our traditional business area while we move into the new and exciting generics segment confirms that Navamedic's strategy is proving successful," said CEO Olof Milveden.

Navamedic sales in the fourth quarter were NOK 19.2 million, which is a 22 per cent growth over the previous year's fourth quarter. Sales were mainly attributable to the Vitaflo business area, however the new Generics business area posted sales for the first time with revenues of NOK 0.1 million.

While Vitaflo profitability continues to improve, Navamedic's group results are affected by costs related to the build-up of its new generics business. The Group's EBITDA came in at NOK 0.3 for the quarter, a significant improvement over the corresponding quarter last year.

Navamedic launched its two first generic drugs in the fourth quarter and is well underway towards building a position in this fast growing segment. The Company currently has 11 generic products filed for approval and expects to launch eight of these in the market during 2012. Generics developing costs and capitalised investments in the business area totalled NOK 5.7 million in the fourth quarter.

The Vitaflo business area, which is a distributor of health care products and patented drugs in the Nordic markets, experienced high sales growth also in the fourth quarter. Profitability continued to improve and the EBITDA margin reached 10 per cent in the fourth quarter.

For the full year, Navamedic's sales grew by almost 30 per cent and reached NOK 71.3 million. EBITDA after generics development costs came in at NOK -2.6 million, a significant improvement over the previous year's EBITDA of NOK -6.5 million.

Navamedic forecasts continued double digit sales growth and attractive margins in its Vitaflo business area. As generics products are rolled out during 2012, the Company expects profitability also in this area towards the end of the year.

Related news

Latest news

PRESS RELEASE: Servogear to propel Asian built windfarm vessels

The contract with Cheoy Lee Shipyards was signed in Q2 2018.

SERVICEBULLETIN: Grease filling of the propeller system

SERVICEBULLETIN 180921: Grease filling of the propeller system

FILM: The world´s first HD220 gearbox returns for an overhauling

The gearbox has been operating flawlessly for more than 20.000 hours...

Øveraasen delivers machine number 66 to New York

Totally over the last ten years, 

DNV GL commission worlds largest industrial explosion chamber at Spadeadam Research and Testing

The chamber supports not only a joint industry project ...

DNV GL celebrates double win at Lloyd’s List Asia Pacific Awards

We would like to thank all of the judges and Lloyd’s List for these awards,

WITH OR WITHOUT SKIRTINGS?

A theme that often comes back to me while working with new customers is the flooring,

Heating cable segment officially transferred to ØS Varme

Øglænd System AS’s future strategy will be focused on the sale...

Genesis is celebrating its 30th anniversary

TechnipFMC’s market-leading engineering and advisory company,